![conference banner](/images/conference-banner.jpeg)
摘要
背景:伏多西汀是一种多式抗抑郁药,用于治疗重度抑郁症和焦虑症。本综述的目的是定量地综合所有有关伏多西汀治疗焦虑症的有效性、安全性和耐受性的数据。方法:“伏多西汀”或“LuAA 21004”和“焦虑”、“恐惧”或“恐慌”或“恐惧”或“恐慌”。“恐惧症”被搜索,共发现了两个阶段的Ⅱ期和五个阶段的临床试验。 结果:与安慰剂相比,沃硫西汀总体上优于安慰剂-8周时的总评分为-2.95,95%cis,-4.37至-1.53,p<0.01。与安慰剂相比,5 mg伏多西汀的有效率更高(集合优势比=1.4,95%ci=1.08~1.82,p=0.01)。然而,伏他西汀组和安慰剂组HAMA缓解率的合并优势比均无统计学意义(合并优势比=1.06,95%Ci=0.86~1.30,p=0.62),但由于不良反应而停用的发生率高于安慰剂组(合并或=1.55,95%ci=1.04~2.31,p=0.037),但无效(合并或=0.39,95%ci=0.27~0.57,p<0.037)。安慰剂组高于伏罗西汀组,不良反应多为轻度和中度,总体上显示出较好的安全性和耐受性。 结论:本综述支持使用伏多西汀治疗焦虑症,然而,进一步的长期安慰剂对照观察研究或市场后调查将有助于加强这种治疗方式的证据。
关键词: 沃蒂奥西汀,焦虑症,LuAA 21004,广泛性焦虑症,5-羟色胺部分激动剂再摄取抑制剂(SPAI)。
Current Drug Targets
Title:Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study
Volume: 19 Issue: 12
关键词: 沃蒂奥西汀,焦虑症,LuAA 21004,广泛性焦虑症,5-羟色胺部分激动剂再摄取抑制剂(SPAI)。
摘要: Background: Vortioxetine is a multimodal antidepressant that has been developed for the treatment of major depressive and anxiety disorders. The aim of this review is to quantitatively synthesize all data of the efficacy, safety and tolerability of Vortioxetine in treating anxiety disorder.
Method: Terms of “Vortioxetine” OR “LuAA21004” AND “anxiety” OR “fear” OR “panic” OR “phobia” were searched. A total of two phase II and five phase III clinical trials were found.
Results: Vortioxetine was overall superior to placebo in terms of the mean change from baseline in HAM-A total score at week 8 with the pool effect size of -2.95, 95% CIs, -4.37 to -1.53, p<0.01. The patients who received 5 mg of Vortioxetine had higher response rate when compared to placebo (pooled odds ratio=1.4, 95% CI = 1.08 to 1.82, p=0.01). However, the pooled odds ratio of the HAMA remission rate was not statistically significant for both Vortioxetine and placebo (pooled odds ratio= 1.06, 95% CI = 0.86 to 1.30, p=0.62). Although the discontinuation due to adverse effects was higher in Vortioxetine than placebo group (pooled OR= 1.55, 95% CI = 1.04 to 2.31, P= 0.037), the lack of efficacy (pooled OR= 0.39, 95% CI = 0.27 to 0.57, P<0.01) was higher in placebo than Vortioxetine group. Most of the adverse effects were mild and moderate. Overall, Vortioxetine displayed a good safety and tolerability profile.
Conclusion: This review supports the use of Vortioxetine for anxiety disorder. However, further longterm placebo-control observational study or a post market survey would help in strengthening the evidence for this treatment modality.
Export Options
About this article
Cite this article as:
Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study, Current Drug Targets 2018; 19 (12) . https://dx.doi.org/10.2174/1389450118666171117131151
DOI https://dx.doi.org/10.2174/1389450118666171117131151 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurocognitive Correlates in Driving Under the Influence of <I>Cannabis</i>
CNS & Neurological Disorders - Drug Targets RNA as a Drug Target: Recent Patents on the Catalytic Activity of Trans- Splicing Ribozymes Derived from Group I Intron RNA
Recent Patents on DNA & Gene Sequences There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Current Alzheimer Research The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Commonalities and Differences Between Crohns Disease and Ulcerative Colitis: The Genetic Clues to their Interpretation
Inflammation & Allergy - Drug Targets (Discontinued) Limonin, A Citrus Limonoid, had no Apparent Effect on Cognitive Dysfunction in Mice with Chronic Cerebral Hypoperfusion
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Therapeutic Properties of Several Chemical Compounds of <i>Salvia officinalis</i> L. in Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeo - static Signaling
Current Psychopharmacology Diagnosis of Alzheimer's Disease Based on Deeply-Fused Nets
Combinatorial Chemistry & High Throughput Screening Multiscale Molecular Dynamics of Protein Aggregation
Current Protein & Peptide Science Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Long Term Outcome of Infants with NEC
Current Pediatric Reviews